A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind,
placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.